Friday, October 12, 2012

13:00 – 13:15 Welcome and Introductions
Carla Baan, PhD, Rotterdam, The Netherlands
Roslyn Mannon, MD, Birmingham, United States

13:15 – 13:45 Keynote Address
Cell Therapy in Transplantation: The Time is Here
Edward Geissler, PhD, Regensburg, Germany

13:45 – 15:15 Optimizing Costimulation Blockade
Chairs: Barbara Murphy, MD, New York, United States and
Thomas Wekerle, MD, Vienna, Austria

13:45 Costimulation Blockade: Review of Clinical Trials
Lionel Rostaing, MD, PhD, Toulouse, France

14:15 Improving Clinical Outcomes of Costimulation Blockade:
Lessons from the Bench
Mohamed Sayegh, MD, Boston, United States and Beirut, Lebanon

14:45 New Costimulation Blockades: Anti CD40 and the Rest of the Pipeline
Flavio Vincenti, MD, San Francisco, United States

15:15 – 15:30 Break

15:30 – 17:00 B-Cells and Antibody-Mediated Rejection
Chairs: Christophe Legendre, MD, Paris, France and
Stefan Schneeberger, MD, Innsbruck, Austria

15:30 B-Cell Regulation
Menna Clatworthy, MD, PhD

16:00 Diagnosis of Antibody-Mediated Rejection
Alexandre Loupy, MD, PhD, Paris, France

16:30 Management of Antibody-Mediated Rejection
Christophe Legendre, MD, Paris, France

17:00 – 18:00 Individualized Immunosuppression
Chairs: Teun van Gelder, MD, PhD, Rotterdam, The Netherlands and
Mohamed Sayegh, MD, Boston, United States and Beirut, Lebanon

17:00 How to Achieve True Individualized Therapy:
Gene Sequencing, Biomarkers
Andrew Kasarskis, PhD, New York, United States

17:30 Clinical Relevance of Pharmacogenetics of Recipients and Donors
Dirk Kuypers, MD, PhD, Leuven, Belgium

18:00 – 19:30 Welcome Reception with Posters and Exhibits
Saturday, October 13, 2012

09:00 – 10:30 **Biomarkers**
Chairs: Teun van Gelder, MD, PhD, *Rotterdam, The Netherlands* and Rutger Ploeg, MD, PhD, *Oxford, United Kingdom*

09:00 Immune Surveillance in Clinical Trials: What Did We Learn from RISET?
Birgit Sawitzki, PhD, *Berlin, Germany*

09:30 Clinical Trials in Organ Transplantation (CTOT)
Donald Hricik, MD, *Cleveland, United States*

10:00 – 10:30 Break

10:30 – 11:30 **Current Pipelines in Biotech and Pharma**
Chairs: Klemens Budde, MD, *Berlin, Germany* and Flavio Vincenti, MD, *San Francisco, United States*

Presentations from Biotech Companies and Pharmaceutical Companies

11:30 – 12:30 **Small Molecules in the Pipeline**
Chairs: Carla Baan, PhD, *Rotterdam, The Netherlands* and Robert Gaston, MD, *Birmingham, United States*

11:30 Sotrastaurin
Klemens Budde, MD, *Berlin, Germany*

12:00 Tofacitinib
Flavio Vincenti, MD, *San Francisco, United States*

12:30 – 14:30 **Long-term Outcomes in Kidney Transplantation with T-cell Costimulation Blockade**
Bristol-Myers Squibb Luncheon Symposium

14:30 – 14:45 Break

14:45 – 16:15 **Unfulfilled Targets in Transplantation**
Chairs: Thomas Wekerle, MD, *Vienna, Austria* and Donald Hricik, MD, *Cleveland, United States*

14:45 Il6 and Il17: Should These Cytokines Be Targeted?
Carla Baan, PhD, *Rotterdam, The Netherlands*

15:15 Targeting Memory Cells: The Next Hurdle
Allan Kirk, MD, PhD, *Atlanta, United States*

15:45 The Case for Targeting Complement
Peter Heeger, MD, *New York, United States*

16:15 – 17:45 **Challenging Medical Decisions**
Chair: Klemens Budde, MD, *Berlin, Germany*

16:15 Desensitize or Donor Swap?
Robert Gaston, MD, *Birmingham, United States*

16:45 Unacceptable Mismatches
Frans Claas, PhD, *Leiden, The Netherlands*

17:15 The mTor-inhibitor Dilemma: Who Benefits and Who Does Not
Josep Grinyó, MD, *Barcelona, Spain*
9:00 – 10:15 Moderated Walk-Around Poster Session
with Breakfast

10:15 – 11:15 The Unmet Needs

10:15 New Molecules for Delayed Graft Function
Bernd Schröppel, MD, New York, United States

10:45 New Molecules for Fibrosis
Roslyn Mannon, MD, Birmingham, United States

11:15 – 11:45 Break

11:45 – 12:45 Controversies in Transplantation

11:45 What Is Currently Considered Optimal Therapy and
Why Is It Still Failing Us in the Long-term?
Christophe Legendre, MD, Paris, France

12:15 Is Chronic Rejection Inevitable?
Barbara Murphy, MD, New York, United States